Showing 801 - 820 results of 100,843 for search '(( 5 point decrease ) OR ( 5 ((((mean decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.51s Refine Results
  1. 801
  2. 802

    FABP5 overexpression decreases inflammation and increases innate immunity in primary NHBE cells. by Fabienne Gally (260470)

    Published 2013
    “…<p><b>A.</b> CS exposure decreases <i>P. aeruginosa</i> colony forming units (CFU) on primary NHBE cells overexpressing FABP5. …”
  3. 803
  4. 804
  5. 805
  6. 806
  7. 807
  8. 808
  9. 809
  10. 810

    Tau phosphorylation is decreased in neurons treated with 20 mM KCl. by Nguyen-Vi Mohamed (323606)

    Published 2017
    “…The phosphorylation of S199/S202, T181, T205 and S404 was not significantly affected by 10mM of KCl treatment whereas the phosphorylation of all these sites was decreased by 20mM of KCl treatment. The signal of the phospho-antibodies was normalized to that of total Tau (n = 5, mean ± SEM, unpaired t-test two-tailed, *<i>P</i> < 0.05, ***<i>P</i> < 0.001). …”
  11. 811

    A R13A point mutation in C4 attenuates CLCuMuV infection. by Asigul Ismayil (5698946)

    Published 2018
    “…<i>eIF4α</i> was used as an internal control. Values represent means ± SE from three independent experiments. <b>(C)</b> The mutant CLCuMuV carrying C4<sup>R13A</sup> (CLCuMuV-C4<sup>R13A</sup>), which contains a R13A mutation in <i>C4</i>, showed the decreased viral symptom compared to wild type CLCuMuV. …”
  12. 812
  13. 813
  14. 814
  15. 815
  16. 816
  17. 817
  18. 818

    Structure of YOLOv5s-SBC. by Zhongjian Xie (4633099)

    Published 2024
    “…Compared to the original model, P-YOLOv5s-GRNF decreased parameters by 18%, decreased model size to 11.9MB, decreased FLOPs to 14.5G, and increased FPS by 4.3. …”
  19. 819
  20. 820

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”